The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents-Reference-Cited by-同舟云学术

The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents

Published:2015-01 Issue:2 Volume:356 Page:686-696
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Shen Xing,Xiong Guo-Lin,Jing Yu,Xiao He,Cui Yu,Zhang Yan-Feng,Shan Ya-Jun,Xing Shuang,Yang Meng,Liu Xiao-Lan,Dong Bo,Wang Li-Sheng,Luo Qing-Liang,Yu Zu-Yin,Cong Yu-Wen

Funder

Nature Science Foundation of China

Chinese Science and Technology Major Projects

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Stem cells in normal and leukemic hemopoiesis;McCulloch;Blood,1983

2. The difficult problem of acute myeloid leukemia in the older adult;Stone;CA Cancer J. Clin,2002

3. Acute promyelocytic leukemia: from highly fatal to highly curable;Wang;Blood,2008

4. Protein kinase C and other diacylglycerol effectors in cancer;Griner;Nat. Rev. Cancer,2007

5. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis;Redig;J. Interferon Cytokine Res,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein kinase C signaling “in” and “to” the nucleus: Master kinases in transcriptional regulation;Journal of Biological Chemistry;2024-03

2. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers;Proceedings of the National Academy of Sciences;2024-02-20

3. Fluacrypyrim Protects Hematopoietic Stem and Progenitor Cells against Irradiation via Apoptosis Prevention;Molecules;2024-02-09

4. Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation;Nature Communications;2023-10-30

5. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer;Cancer Letters;2022-04